Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.7 USD | -0.66% | +4.19% | -19.35% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.35% | 2.4B | |
+17.94% | 47.02B | |
+48.77% | 41.86B | |
+0.85% | 41.76B | |
-4.27% | 28.8B | |
+12.16% | 26.05B | |
-21.15% | 19.15B | |
+4.39% | 12.55B | |
+28.51% | 12.34B | |
-4.36% | 11.82B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Wedbush Lowers Price Target for Intellia Therapeutics to $55 From $108, Maintains Neutral Rating